OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Franses on the Feasibility of Co-Inhibiting Angiogenesis and PD-1 Pathways in HCC

June 28th 2024

Joseph Franses, MD, PhD, debates whether targeting angiogenesis and the PD-1/PD-L1 pathway in hepatocellular carcinoma is always a reliable approach.

Dr Owonikoko on the Impact of the FDA Approval of Tarlatamab in ES-SCLC

June 28th 2024

Taofeek Owonikoko, MD, PhD, expands on the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.

Dr Chao on the Association Between Broad-Spectrum Antibiotic Use and the Risk of Early-Onset CRC

June 28th 2024

Chun Chao, MS, PhD, discusses the impact of broad-spectrum antibiotic use on the risk of developing early-onset colorectal adenocarcinoma.

Dr Llombart-Cussac on Preventing Neutropenia and Diarrhea in HR+/HER2– Advanced Breast Cancer

June 28th 2024

Antonio Llombart-Cussac, MD, PhD, discusses preventing neutropenia and diarrhea with sacituzumab govitecan in HR+/HER2– advanced breast cancer.

Dr Kyriakopoulos on Evaluating Biomarkers and Disease Progression with CTC Analysis in CHAARTED2 trial

June 28th 2024

Christos Kyriakopoulos, MD discusses two correlative studies conducted within the CHAARTED2 trial.

Dr Pothuri on Real-World Treatment Patterns Per MMR/MSI Status in Endometrial Cancer

June 27th 2024

Bhavana Pothuri, MD, discusses real-world treatment patterns and outcomes in patients with advanced endometrial cancer according to MMR/MSI status.

Dr Fakih on OS Data for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

June 27th 2024

Marwan G. Fakih, MD, discusses data for sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Dr O'Shaughnessy on MammaPrint H1 vs H2 Status on 3-year RFS in HR+, HER2– Breast Cancer

June 27th 2024

Joyce O'Shaughnessy, MD, on the impact of MammaPrint H1 and H2 status on 3-year relapse-free survival in HR-positive, HER2-negative early breast cancer.

Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCL

June 27th 2024

Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.

Dr O'Malley on Updates in Gynecologic Oncology at the 2024 ASCO Annual Meeting

June 27th 2024

David M. O’Malley, MD, and Chandler H. Park, MD, FACP, discuss updates in gynecologic oncology at the 2024 ASCO Annual Meeting.

Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma

June 27th 2024

Mohamad Mohty, MD, PhD, discusses the real-world efficacy of elranatamab in patients with relapsed/refractory multiple myeloma.

Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting

June 27th 2024

Suresh S. Ramalingam, MD, FACP, FASCO, and Chandler H. Park, MD, FACP, discuss updates in non–small cell lung cancer at the 2024 ASCO Annual Meeting.

Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCC

June 27th 2024

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab in the treatment of patients with cutaneous squamous cell carcinoma.

Dr Cigliola on the Efficacy of Sacituzumab Govitecan in MIBC

June 27th 2024

Antonio Cigliola, MD, discusses interim efficacy data from the SURE-01 study investigating neoadjuvant sacituzumab govitecan in patients with MIBC.

Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL

June 27th 2024

Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.

Dr Waks on Unmet Needs in Patients With HER2+ Breast Cancer

June 26th 2024

Adrienne G. Waks, MD, discusses efforts to address unmet needs in HER2-positive breast cancer.

Dr Parikh on Outcomes from the HERKULES-3 Trial in BRAF V600E–Mutant mCRC

June 26th 2024

Aparna Parikh, MD, discusses outcomes from the HERKULES-3 trial in BRAF V600E–mutated metastatic colorectal cancer.

Dr Ghia on Long-Term Efficacy With Acalabrutinib Monotherapy in CLL

June 26th 2024

Paolo Ghia, MD, PhD, discusses long-term follow-up data from a pooled analysis evaluating the efficacy of acalabrutinib monotherapy in CLL.

Dr Ignatz-Hoover on the Future of CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma

June 26th 2024

James Ignatz-Hoover, MD, PhD, discusses the future of CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma.

Dr Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer

June 26th 2024

David Rimm, MD, PhD, discusses challenges in distinguishing between HER2-low and HER2-ultralow breast cancer using current diagnostic kits.